Arthrosi Therapeutics
LAGUNA HILLS, CA · Biotechnology, Healthcare, Manufacturing · 39 employees
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope.
Funding history
- Series E — $153.0M — Oct 2025
- Venture - Series Unknown — $60.9M — Jun 2025
- Venture - Series Unknown — $7.0M — Jan 2024
- Venture - Series Unknown — $15.0M — Mar 2023
- Venture - Series Unknown — $26.0M — Nov 2021
Recent signals
- Oct 08, 2025: Raised $153.0M in Series E
- Jun 24, 2025: Raised $60.9M in Venture - Series Unknown
- Jan 26, 2024: Raised $7.0M in Venture - Series Unknown
- Mar 03, 2023: Raised $15.0M in Venture - Series Unknown
- Nov 15, 2021: Raised $26.0M in Venture - Series Unknown
- Nov 15, 2021: Raised $220K in Venture - Series Unknown
- Jun 03, 2020: Raised $8.5M in Venture - Series Unknown
- Jan 30, 2019: Raised $11.0M in Venture - Series Unknown
See plans & pricing → Track Arthrosi Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.